Medical device company Hyperfine has launched its AI-powered eighth generation of the Swoop system software for improved brain imaging.

This software, which has received both CE and UK Conformity Assessed (UKCA) approval, features an FDA-approved diffusion-weighted imaging (DWI) AI denoising tool.

The new software also aims to improve the Swoop system's image quality and streamline its operation. It includes a real-time aid for more accurate patient loading and positioning, as well as a simplified image upload process.

During the limited market release phase, more than 50 exams were conducted at participating hospitals, resulting in positive feedback on the DWI image quality.

The new features, particularly the fast-positioning check and the streamlined upload process, have been acknowledged for significantly reducing upload times and aiding in better image acquisition.

In the coming weeks, Hyperfine plans to deploy the software updates to Swoop system users.

Hyperfine chief operating officer Tom Teisseyre said: “Our latest AI-powered software, the eighth generation of our proprietary software platform, embodies our commitment to supporting clinicians in critical decision-making.

“Our focus on image quality with this latest software has been on the DWI sequence, which is key in stroke imaging. Since its first FDA clearance in 2020, we’ve been dedicated to continually enhancing image quality and workflow efficiencies to define best-in-class, user-centric, ultra-low field MR brain imaging.”

Last year, Jefferson Abington Hospital in the US deployed the Hyperfine Swoop portable MR imaging system for clinical use and to improve the way patients receive brain imaging.

Commenting on the latest update, Radiology Group of Abington neuroradiologist Jennifer Villa Frabizzio said: “The software update on the Swoop system has been most beneficial to our workflow.

“We are now able to view each series as it is being performed and can communicate with the technologist whether additional series are needed. Additionally, we can communicate with clinicians any critical findings in real-time without having to wait for the whole study to be completed.”

Hyperfine’s Swoop system received its initial FDA approval in 2020.